Editas Medicine Inc
Company Profile
Business description
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
Contact
11 Hurley Street
CambridgeMA02141
USAT: +1 617 401-9000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
226
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,777.90 | 50.80 | -0.58% |
CAC 40 | 7,794.65 | 27.94 | 0.36% |
DAX 40 | 24,275.32 | 68.41 | 0.28% |
Dow JONES (US) | 44,240.76 | 165.60 | -0.37% |
FTSE 100 | 8,868.31 | 14.13 | 0.16% |
HKSE | 23,876.70 | 271.37 | -1.12% |
NASDAQ | 20,418.46 | 5.95 | 0.03% |
Nikkei 225 | 39,821.28 | 132.47 | 0.33% |
NZX 50 Index | 12,768.61 | 90.41 | -0.70% |
S&P 500 | 6,225.52 | 4.46 | -0.07% |
S&P/ASX 200 | 8,538.60 | 52.10 | -0.61% |
SSE Composite Index | 3,493.05 | 4.43 | -0.13% |